CA1297021C - Therapeutic agent for the treatment of peptic ulcer disease - Google Patents
Therapeutic agent for the treatment of peptic ulcer diseaseInfo
- Publication number
- CA1297021C CA1297021C CA000548615A CA548615A CA1297021C CA 1297021 C CA1297021 C CA 1297021C CA 000548615 A CA000548615 A CA 000548615A CA 548615 A CA548615 A CA 548615A CA 1297021 C CA1297021 C CA 1297021C
- Authority
- CA
- Canada
- Prior art keywords
- therapeutic agent
- treatment
- compound
- peptic ulcer
- ulcer disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP236078/86 | 1986-10-06 | ||
| JP23607886 | 1986-10-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1297021C true CA1297021C (en) | 1992-03-10 |
Family
ID=16995393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000548615A Expired - Lifetime CA1297021C (en) | 1986-10-06 | 1987-10-05 | Therapeutic agent for the treatment of peptic ulcer disease |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4845102A (enEXAMPLES) |
| EP (1) | EP0266559B1 (enEXAMPLES) |
| JP (1) | JPS63225317A (enEXAMPLES) |
| KR (1) | KR950007101B1 (enEXAMPLES) |
| AT (1) | ATE75399T1 (enEXAMPLES) |
| AU (1) | AU595379B2 (enEXAMPLES) |
| CA (1) | CA1297021C (enEXAMPLES) |
| DE (1) | DE3778642D1 (enEXAMPLES) |
| DK (1) | DK169305B1 (enEXAMPLES) |
| ES (1) | ES2032797T3 (enEXAMPLES) |
| GR (1) | GR3004848T3 (enEXAMPLES) |
| HU (1) | HU200098B (enEXAMPLES) |
| IE (1) | IE60863B1 (enEXAMPLES) |
| IL (1) | IL84096A (enEXAMPLES) |
| PT (1) | PT85866B (enEXAMPLES) |
| ZA (1) | ZA877454B (enEXAMPLES) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2661666B2 (ja) * | 1988-02-19 | 1997-10-08 | ヘキスト薬品工業株式会社 | 抗消化性潰瘍剤 |
| DD298051A5 (de) * | 1989-08-16 | 1992-02-06 | ��@���������@�������k�� | Verfahren zur herstellung eines therapeutischen agens zur behandlung von verdauungskrankheiten |
| DE4025371A1 (de) * | 1990-08-10 | 1992-02-13 | Kali & Salz Ag | Verfahren zur reinigung von elektrostatisch gewonnenem steinsalz |
| EP0570831A2 (de) * | 1992-05-20 | 1993-11-24 | Hoechst Aktiengesellschaft | Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation |
| US6693105B1 (en) | 1992-11-16 | 2004-02-17 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
| US5804584A (en) * | 1992-11-16 | 1998-09-08 | Cell Therapeutics, Inc. | Therapeutic compounds containing a monocyclic five- to six- membered ring structure having one to two nitrogen atoms |
| US20030207901A1 (en) * | 1999-07-27 | 2003-11-06 | Cell Therapeutics, Inc. | Hydroxyl-containing compounds |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2330742C2 (de) * | 1973-06-16 | 1982-07-29 | Hoechst Ag, 6000 Frankfurt | 1-(Oxoalkyl)-3-methyl-7-alkylxanthine, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel |
| CH608236A5 (enEXAMPLES) * | 1974-01-22 | 1978-12-29 | Wuelfing J A Fa | |
| CA1075690A (en) * | 1974-12-13 | 1980-04-15 | Hoechst Aktiengesellschaft | Xanthine derivatives |
| US4511557A (en) * | 1981-08-24 | 1985-04-16 | Gauri Kailash Kumar | Pharmaceutical composition |
| IT1200944B (it) * | 1982-08-10 | 1989-01-27 | Malesci Sas | Derivati xantinici,procedimento per la loro preparazione,composizione farmaceutiche che il contengono e loro impiego terapeutico |
| US4636507A (en) * | 1984-04-30 | 1987-01-13 | Hoechst-Roussel Pharmaceuticals Inc. | Host defense mechanism enhancement |
-
1987
- 1987-09-24 JP JP62237540A patent/JPS63225317A/ja active Pending
- 1987-10-01 DE DE8787114328T patent/DE3778642D1/de not_active Expired - Lifetime
- 1987-10-01 EP EP87114328A patent/EP0266559B1/en not_active Expired - Lifetime
- 1987-10-01 AT AT87114328T patent/ATE75399T1/de active
- 1987-10-01 ES ES198787114328T patent/ES2032797T3/es not_active Expired - Lifetime
- 1987-10-02 US US07/103,816 patent/US4845102A/en not_active Expired - Fee Related
- 1987-10-05 AU AU79358/87A patent/AU595379B2/en not_active Ceased
- 1987-10-05 IL IL84096A patent/IL84096A/xx not_active IP Right Cessation
- 1987-10-05 IE IE265687A patent/IE60863B1/en not_active IP Right Cessation
- 1987-10-05 CA CA000548615A patent/CA1297021C/en not_active Expired - Lifetime
- 1987-10-05 ZA ZA877454A patent/ZA877454B/xx unknown
- 1987-10-05 HU HU874468A patent/HU200098B/hu not_active IP Right Cessation
- 1987-10-05 DK DK520787A patent/DK169305B1/da not_active IP Right Cessation
- 1987-10-06 PT PT85866A patent/PT85866B/pt not_active IP Right Cessation
- 1987-10-06 KR KR1019870011129A patent/KR950007101B1/ko not_active Expired - Fee Related
-
1992
- 1992-06-05 GR GR920401188T patent/GR3004848T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0266559A2 (en) | 1988-05-11 |
| EP0266559A3 (en) | 1990-06-06 |
| GR3004848T3 (enEXAMPLES) | 1993-04-28 |
| EP0266559B1 (en) | 1992-04-29 |
| DK520787D0 (da) | 1987-10-05 |
| HUT46214A (en) | 1988-10-28 |
| IL84096A0 (en) | 1988-03-31 |
| US4845102A (en) | 1989-07-04 |
| DE3778642D1 (de) | 1992-06-04 |
| KR950007101B1 (ko) | 1995-06-30 |
| DK520787A (da) | 1988-04-07 |
| IL84096A (en) | 1991-07-18 |
| KR880004810A (ko) | 1988-06-27 |
| HU200098B (en) | 1990-04-28 |
| JPS63225317A (ja) | 1988-09-20 |
| IE60863B1 (en) | 1994-08-24 |
| ATE75399T1 (de) | 1992-05-15 |
| AU595379B2 (en) | 1990-03-29 |
| ZA877454B (en) | 1988-05-25 |
| AU7935887A (en) | 1988-04-14 |
| ES2032797T3 (es) | 1993-03-01 |
| DK169305B1 (da) | 1994-10-10 |
| IE872656L (en) | 1988-04-06 |
| PT85866A (en) | 1987-11-01 |
| PT85866B (pt) | 1990-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1297021C (en) | Therapeutic agent for the treatment of peptic ulcer disease | |
| JP2025027020A (ja) | 患者において血清リン酸塩を低下させるための組み合わせ | |
| ES2215327T3 (es) | Composicion de medicamento inmunomodulador. | |
| JP2661666B2 (ja) | 抗消化性潰瘍剤 | |
| JP2726999B2 (ja) | イミダゾ［２，１−ｂ］ベンゾチアゾール誘導体及び該化合物を有効成分とする抗潰瘍剤 | |
| JP2665357B2 (ja) | 心不全治療用医薬組成物 | |
| AU624987B2 (en) | Therapeutic agents for the treatment of peptic ulcer disease | |
| US5030630A (en) | Use of 6-allyl-2-amino-5,6,7,8-tetrahydro-4H-thiazolo[4,5-d]azepine- for treating diseases caused by reduced secretion of growth hormone | |
| KR20050002925A (ko) | 위 음식물 수용능 장해 치료약 | |
| JP3254712B2 (ja) | 医薬組成物 | |
| JP4426654B2 (ja) | 免疫調節用医薬組成物 | |
| KR102781531B1 (ko) | 피리메타민을 유효성분으로 포함하는 크론병의 치료 또는 예방용 약학 조성물 | |
| WO1994003172A1 (fr) | Remede destine aux troubles inflammatoires de l'intestin | |
| WO2007000771A2 (en) | Fused quinazolinone derivatives and uses thereof | |
| CN109730990B (zh) | 15-苄亚基-14-脱氧-11,12-脱氢穿心莲内酯衍生物在抗纤维化药物中的应用 | |
| WO2025074271A1 (en) | Myt1 inhibitors for the treatment of cancers harboring replication stress mutations | |
| JPH035425A (ja) | 抗潰瘍剤 | |
| JP2621382B2 (ja) | 尿酸排泄剤 | |
| JPH1192373A (ja) | 胃粘膜保護剤 | |
| HUT69718A (en) | Pharmaceutical compositions containing triazolil(thio)quinoline derivatives | |
| JPH04506341A (ja) | ソマトスタチン活性ポリペプチドを活性成分とする医薬組成物 | |
| JPH0881374A (ja) | 皮膚そう痒症の予防または治療薬 | |
| JPH02138216A (ja) | 消化管疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKLA | Lapsed |